Rxrx stock forecast.
"Over the next 10 years, AI could increase productivity by 1.5% per year. And that could increase S&P500 profits by 30% or more over the next decade," Goldman Sach's senior strategist Ben Snider ...
After announcing that it would get a $50 million investment from NVIDIA ( NVDA 0.67%) on July 12, Recursion Pharmaceuticals ( RXRX 0.43%) saw its stock blast off, rising 87% over the following two ...For a biotech like Recursion Pharmaceuticals (RXRX 0.43%) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and …Jul 21, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (7.88%) $0.54. Current Price. $7.39. ... Recursion's stock is up 73% this year, and while it doesn't have any recurring ... Earnings for Recursion Pharmaceuticals are expected to decrease in the coming year, from ($1.67) to ($1.91) per share. Recursion Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 26th, 2024 based off prior year's report dates. Read More.Sep 20, 2022 · Zillow is worth $8.3 billion right now, so if it reaches its 2025 sales estimate and continues to grow thereafter, it should breeze past a $10 billion valuation by 2030. 2. Duolingo: Potential ...
Jul 21, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (7.88%) $0.54. Current Price. $7.39. ... Recursion's stock is up 73% this year, and while it doesn't have any recurring ... You can view all of the due diligence checks on RXRX's stock page. How is RXRX stock valued? You can. use many financial metrics, analyses, models, and charts to gauge RXRX's intrinsic value.Using relative valuations . metrics:RXRX; could be undervalued based on its P/B ratio of 3.35x, relative to Biotechnology industry P/B ratio of . 5.36xThroughout the U.S., the weather can be quite unpredictable, even with state-of-the-art radar, sensors and computer modeling technology right at meteorologists’ fingertips. The Old Farmer’s Almanac first provided valuable statistics and dat...
NSD:RXRX Detailed Stock Analysis, Stock Price Forecast, Analyst Ratings, Financial Analysis, Stock News & Historic QuotesThe 7 analysts offering 1 year price forecasts for RXRX have a max estimate of — and a min estimate of —. Analyst rating Based on 7 analysts giving stock ratings to RXRX in the past 3 months.
As of Monday, August 07, Recursion Pharmaceuticals Inc’s RXRX share price has dipped by 11.05%, which has investors questioning if this is right time to buy. Premium ... Whether you decide it’s a good time to buy or sell Recursion Pharmaceuticals Inc’s stock based on its stock price forecast is ultimately up to you.The Recursion Pharmaceuticals, Inc. stock price gained 1.18% on the last trading day (Friday, 24th Nov 2023), rising from $6.78 to $6.86. During the last trading day the stock fluctuated 5.06% from a day low at $6.71 to a day high of $7.05. The price has risen in 7 of the last 10 days and is up by 31.17% over the past 2 weeks.About the Recursion Pharmaceuticals, Inc. Class A Common Stock stock forecast. As of 2023 December 02, Saturday current price of RXRX stock is 6.910$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. Recursion Pharmaceuticals stock price has been showing a declining tendency so we …November 10, 2023 at 5:06 AM · 3 min read. With a price-to-sales (or "P/S") ratio of 23.8x Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX) may be sending very bearish signals at the moment, given ...
13 июл. 2023 г. ... #price and rxrx stock #chart. Furthermore it explains you the rxrx stock #forecast and how to do rxrx stock prediction. It will also help ...
Shares of Recursion Pharmaceuticals (RXRX 4.89%) were skyrocketing 82% higher this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence.
Welcome to Recursion: The Future of TechBio. Decoding Biology To Radically Improve Lives. Explore Our Story: We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical company. It’s complex biology, decoded.Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...The company raised guidance for annual organic revenue growth from an earlier forecast of between 5% and 7% to between 6% and 8%. It also raised annual adjusted EPS to be between $3.70 and $3.85 ...Investors looking for stocks that can put up dramatic gains ... (RXRX 7. 88%) have fallen by ... Zynteglo's U.S. launch will be extra difficult to forecast because its strategy involves returning ...Insiders have purchased a total of 581,017 RXRX shares in the last 24 months for a total of $4,440,853.30 bought. Which Recursion Pharmaceuticals insiders have been selling company stock? The following insiders have sold RXRX shares in the last 24 months: Blake Borgeson ($2,846,394.44), Christopher Gibson ($14,439,192.59), …Get the latest Recursion Pharmaceuticals, Inc RXRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.InvestorsObserver is giving Recursion Pharmaceuticals Inc (RXRX) an Analyst Rating Rank of 25, meaning RXRX is ranked higher by analysts than 25% of …
HPQ Stock 12 Months Forecast. $30.18. (14.17% Upside) Based on 11 Wall Street analysts offering 12 month price targets for HP in the last 3 months. The average price target is $30.18 with a high forecast of $39.00 and a low forecast of $23.00. The average price target represents a 14.17% change from the last price of $26.44.Recursion Pharmaceuticals Inc Cl A (RXRX) $7.05 0.38 (5.70%) 16:00 EST RXRX Stock Quote Delayed 30 Minutes.NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (7.88%) $0.54. Current Price. $7.39. ... Recursion's stock is up 73% this year, and while it doesn't have any recurring ...The US$14.13 analyst price target for RXRX is 3.5% ... we will estimate the stock's intrinsic value by taking the forecast future cash flows of the company and discounting them back to today's ...Recursion Pharmaceuticals Inc. research and ratings by Barron's. View RXRX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.Dec 1, 2023 · RXRX Stock Overview. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.
Current. -$0.35. 1 Month Ago. -$0.35. 3 Months Ago. -$0.32. Recursion Pharmaceuticals Inc. analyst estimates, including RXRX earnings per share estimates and analyst recommendations. According to the current price, Recursion Pharmaceuticals, is 42.39% away from the 52-week high. What are analysts forecasts for Recursion Pharmaceuticals, stock? The 21 analysts offering price ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...The US$14.13 analyst price target for RXRX is 3.5% ... we will estimate the stock's intrinsic value by taking the forecast future cash flows of the company and discounting them back to today's ...What are analysts forecasts for Recursion Pharmaceuticals, stock? The 21 analysts offering price forecasts for Recursion Pharmaceuticals, have a median target of 14.62, with a high estimate of 33. ...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Find real-time RPRX - Royalty Pharma PLC stock quotes, company profile, news and forecasts from CNN Business.Jul 21, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (7.88%) $0.54. Current Price. $7.39. ... Recursion's stock is up 73% this year, and while it doesn't have any recurring ... At the close of trading, the stock’s price was $5.09, to imply a decrease of -3.60% or -$0.19 in intraday trading. The RXRX share’s 52-week high remains $16.75, putting it -229.08% down since that peak but still an impressive 10.81% since price per share fell to its 52-week low of $4.54.What is Recursion Pharmaceuticals, Inc. (RXRX) stock EPS forecast? Recursion Pharmaceuticals, Inc. missed analysts’ expectations during the last earnings period by 13.16% . Recursion Pharmaceuticals, Inc. reported earnings of -$ 0.43 per share on Nov 9, 2023, while the forecasted EPS was -$ 0.38.Recursion Pharma may be a biotech stock, but it scored a $50 million investment from Nvidia to fund its AI technology in mid-July - making NVDA a significant stakeholder in RXRX.Get the latest Recursion Pharmaceuticals, Inc RXRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.
View the latest Recursion Pharmaceuticals Inc. (RXRX) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Recursion Pharmaceuticals Inc. 7.06. Delayed Data. As of Nov 17. +0.39 / +5.85%. Today’s Change. 4.54. Today ||| 52-Week Range. 16.75.
Recursion Pharmaceuticals Inc Cl A stocks price quote with latest real-time prices, charts, financials, ... RXRX Related stocks. Symbol 3M %Chg ; RXRX -18.97% : Recursion Pharmaceuticals Inc Cl A: ZTS -6.96% : Zoetis Inc Cl A: TAK ... Cash Markets Overview Corn Indexes Soybean Indexes Yield Forecast Indexes.Recursion Pharmaceuticals Stock Chart and Share Price Forecast, Short-Term "RXRX" Stock Prediction for Next Days and Weeks Walletinvestor.com Recursion Pharmaceuticals Inc (RXRX) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024July 12 (Reuters) - Chip designer Nvidia (NVDA.O) will invest $50 million to speed up training of Recursion's (RXRX.O) artificial intelligence models for drug discovery, the companies said on ...Meta Platforms ( META ): META’s revenues climbed 23% to $34.15 billion in its most recent quarter. Teradyne ( TER ): Resilient Teradyne outshone in the third quarter with an 80-cent Non-GAAP EPS ...The above table shows the analyst RXRX forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$7.39Weather forecasts play an essential role in our daily lives, helping us plan our activities and stay prepared for any weather conditions that may come our way. One of the most common types of forecasts is the 7-day weather forecast, which p...Nov 22, 2023 · The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target for the stock is $15.57, which implies that it could rise by about 120% over the next 12 months. What is Recursion Pharmaceuticals, Inc. (RXRX) stock EPS forecast? Recursion Pharmaceuticals, Inc. missed analysts’ expectations during the last earnings period by 13.16% . Recursion Pharmaceuticals, Inc. reported earnings of -$ 0.43 per share on Nov 9, 2023, while the forecasted EPS was -$ 0.38.Zillow is worth $8.3 billion right now, so if it reaches its 2025 sales estimate and continues to grow thereafter, it should breeze past a $10 billion valuation by 2030. 2. Duolingo: Potential ...Recursion Pharmaceuticals Inc. 7.06. Delayed Data. As of Nov 17. +0.39 / +5.85%. Today’s Change. 4.54. Today ||| 52-Week Range. 16.75.
Explore RXRX - Recursion Pharmaceuticals Inc Stock Price Forecast: Accurate short-term and long-term price predictions up to 2050. ... Stock Calculator; Dow: 35,088. ... Analysts have provided the following ratings for Recursion Pharmaceuticals (NASDAQ:RXRX) within the last quarter: These 7 analysts have an average price target of $18.14 versus the current price ...Find the latest Vacasa, Inc. (VCSA) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W - 6W. Mid Term ...Instagram:https://instagram. criptomonedas precios hoyjnk tickerlist vanguard mutual fundshow to set up a day trading account Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...Current. -$0.35. 1 Month Ago. -$0.35. 3 Months Ago. -$0.32. Recursion Pharmaceuticals Inc. analyst estimates, including RXRX earnings per share estimates and analyst recommendations. active etfsidrv holdings Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.33 per share a year ago. mt5 brokers Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...The above table shows the analyst RXRX forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$7.39